Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III ACYW135 meningococcal conjugate vaccine trial in healthy infants aged 6-23 months
ChiCTR2200058396Phase 3Not yet recruiting
- Sponsor
- Hunan Center for Disease Control and Prevention
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of A, C, Y, W135 meningococcal polysaccharide vaccine in meningococcal disease (5 arms), sponsored by Hunan Center for Disease Control and Prevention. Primary endpoints: Group A meningococcal serum bactericidal activity antibody, Group C meningococcal serum bactericidal activity antibody and 2 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
A, C, Y, W135 meningococcal polysaccharide vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on ChiCTR2200058396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058396.